Plenary Session – inactive due to federal service

4.65 DESTINY BREAST 04 - A complex trial to deconstruct

32 min • 7 juni 2022
My take on the standing ovation for DESTINY Breast 04 Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low

Senaste avsnitt

Podcastbild

00:00 -00:00
00:00 -00:00